Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.

How to buy Checkmate Pharmaceuticals stock | $6.76

Learn how to easily invest in Checkmate Pharmaceuticals stock.

Checkmate Pharmaceuticals, Inc is a biotechnology business based in the US. Checkmate Pharmaceuticals shares (CMPI) are listed on the NASDAQ and all prices are listed in US Dollars. Checkmate Pharmaceuticals employs 25 staff and has a market cap (total outstanding shares value) of 0.00.

How to buy shares in Checkmate Pharmaceuticals

  1. Compare share trading platforms.Use our comparison table to help you find a platform that fits you.
  2. Open your brokerage account. Complete an application with your details.
  3. Confirm your payment details. Fund your account.
  4. Research the stock. Find the stock by name or ticker symbol – CMPI – and research it before deciding if it's a good investment for you.
  5. Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
  6. Check in on your investment. Optimize your portfolio by tracking your stock.

Checkmate Pharmaceuticals stock price (NASDAQ: CMPI)

Use our graph to track the performance of CMPI stocks over time.

Checkmate Pharmaceuticals shares at a glance

Information last updated 2021-07-22.
Latest market close$6.76
52-week range$5.00 - $23.10
50-day moving average $6.04
200-day moving average $10.06
Wall St. target price$22.67
PE ratio N/A
Dividend yield N/A (0%)
Earnings per share (TTM) N/A

Buy Checkmate Pharmaceuticals shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.
Name Product Stock trade fee Asset types Option trade fee Annual fee Signup bonus
Sofi Invest
Stocks, ETFs, Cryptocurrency
Get one free stock worth up to $1,000
Open an account
A free way to invest in stocks, ETFs and crypto.
Stocks, Options, ETFs
Get one free stock valued between $3.00 and $300 when you open an account, one more with a deposit
Open an account
Margin financing rates start at 3.99%. No monthly subscription fees for margin.
Stocks, ETFs
$0 per month
Download and sign up with; approved accounts receive a free stock slice worth up to $70, selected from 9 popular stocks.
Open an account
Commission-free trading in stocks and ETFs with a social networking twist.
J.P. Morgan Self-Directed Investing
Stocks, Bonds, Options, Mutual funds, ETFs
$0 + $0.65/contract
Stocks, Options, ETFs
Free stock (chosen randomly with a value anywhere between $2.50 and $200)
Sign up using the "go to site" link
Make unlimited commission-free trades in stocks, funds, and options with Robinhood Financial.
$0 for US stocks
Stocks, Options, ETFs
$0 per year
Trade stocks on the US, Hong Kong, Shanghai and Shenzhen markets.

Compare up to 4 providers

*Signup bonus information updated weekly.

The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.

Is it a good time to buy Checkmate Pharmaceuticals stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Checkmate Pharmaceuticals price performance over time

Historical closes compared with the close of $6.76 from 2021-05-28

1 week (2021-07-18) N/A
1 month (2021-06-29) 9.39%
3 months (2021-04-29) 5.96%
6 months (2021-01-25) N/A
1 year (2020-07-25) N/A
2 years (2019-07-25) N/A
3 years (2018-07-25) N/A
5 years (2016-07-25) N/A

Checkmate Pharmaceuticals financials

Gross profit TTM $0
Return on assets TTM -43.35%
Return on equity TTM -76.89%
Profit margin 0%
Book value $5.20
Market capitalisation $118.1 million

TTM: trailing 12 months

Shorting Checkmate Pharmaceuticals shares

There are currently 141,671 Checkmate Pharmaceuticals shares held short by investors – that's known as Checkmate Pharmaceuticals's "short interest". This figure is 71.2% down from 491,576 last month.

There are a few different ways that this level of interest in shorting Checkmate Pharmaceuticals shares can be evaluated.

Checkmate Pharmaceuticals's "short interest ratio" (SIR)

Checkmate Pharmaceuticals's "short interest ratio" (SIR) is the quantity of Checkmate Pharmaceuticals shares currently shorted divided by the average quantity of Checkmate Pharmaceuticals shares traded daily (recently around 108977.69230769). Checkmate Pharmaceuticals's SIR currently stands at 1.3. In other words for every 100,000 Checkmate Pharmaceuticals shares traded daily on the market, roughly 1300 shares are currently held short.

However Checkmate Pharmaceuticals's short interest can also be evaluated against the total number of Checkmate Pharmaceuticals shares, or, against the total number of tradable Checkmate Pharmaceuticals shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Checkmate Pharmaceuticals's short interest could be expressed as 0.01% of the outstanding shares (for every 100,000 Checkmate Pharmaceuticals shares in existence, roughly 10 shares are currently held short) or 0.0372% of the tradable shares (for every 100,000 tradable Checkmate Pharmaceuticals shares, roughly 37 shares are currently held short).

Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Checkmate Pharmaceuticals.

Find out more about how you can short Checkmate Pharmaceuticals stock.

Checkmate Pharmaceuticals share dividends

We're not expecting Checkmate Pharmaceuticals to pay a dividend over the next 12 months.

Checkmate Pharmaceuticals overview

Checkmate Pharmaceuticals, Inc. , a clinical-stage biotechnology company, focuses on developing and commercializing novel therapeutics for the treatment of cancer. It develops CMP-001, which is in phase II clinical trial in combination with pembrolizumab to treat patients with PD-1 refractory melanoma; combination with nivolumab to treat patients with PD-1 naïve neoadjuvant melanoma; and treatment in patients with PD-1 refractory melanoma. The company has strategic alliances with Merck KGaA and Pfizer. Checkmate Pharmaceuticals, Inc. was incorporated in 2015 and is headquartered in Cambridge, Massachusetts. .

Stocks similar to Checkmate Pharmaceuticals

Frequently asked questions

What percentage of Checkmate Pharmaceuticals is owned by insiders or institutions?
Currently 10.874% of Checkmate Pharmaceuticals shares are held by insiders and 88.394% by institutions.
How many people work for Checkmate Pharmaceuticals?
Latest data suggests 25 work at Checkmate Pharmaceuticals.
When does the fiscal year end for Checkmate Pharmaceuticals?
Checkmate Pharmaceuticals's fiscal year ends in December.
Where is Checkmate Pharmaceuticals based?
Checkmate Pharmaceuticals's address is: 245 Main Street, Cambridge, MA, United States, 02142
What is Checkmate Pharmaceuticals's ISIN number?
Checkmate Pharmaceuticals's international securities identification number is: US1628181083

More guides on Finder

Ask an Expert

You are about to post a question on

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and Terms of Use.

Questions and responses on are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site